NEW YORK (GenomeWeb News) — Asuragen Pharmacogenomic Services, a division of Asuragen, will develop a biomarker and pharmacogenomic test for a Merck cancer program, Asuragen said today.

 

Terms of the deal call for Asuragen to apply information from an expression signature identified by Merck's oncology research program to develop a diagnostic assay for use in Merck's cancer clinical trials, and to “potentially form the basis for commercial companion diagnostic tests for oncology therapies.”